Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Allogeneic marrow transplantation: the Seattle experience.

J A Hansen1, C Anasetti, P G Beatty

  • 1Division of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, Washington.

Clinical Transplants
|January 1, 1989
PubMed
Summary

Allogeneic marrow transplantation offers life-saving therapy for blood disorders. Advances in donor matching, including unrelated donors and national programs, are expanding patient access to this critical treatment.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Predictors of overall survival among patients treated with sirolimus/tacrolimus vs methotrexate/tacrolimus for GvHD prevention.

Bone marrow transplantation·2017
Same author

Visilizumab with tacrolimus and methotrexate for GvHD prevention after allogeneic hematopoietic cell transplantation from mismatched unrelated donors.

Bone marrow transplantation·2016
Same author

Tacrolimus plus sirolimus with or without ATG as GVHD prophylaxis in HLA-mismatched unrelated donor allogeneic stem cell transplantation.

Bone marrow transplantation·2016
Same author

New sources for argument: do HLA-C and HLA disparity in adult double umbilical cord blood transplants predict outcomes?

Bone marrow transplantation·2016
Same author

Boosting humoral and cellular immunity to pneumococcus by vaccination before and just after autologous transplant for myeloma.

Bone marrow transplantation·2015
Same author

Sirolimus, tacrolimus and antithymocyte globulin as GVHD prophylaxis in HLA-mismatched unrelated donor hematopoietic cell transplantation: a single institution experience.

Bone marrow transplantation·2015

Area of Science:

  • Hematology
  • Immunology
  • Transplantation Medicine

Background:

  • Allogeneic marrow transplantation is a vital treatment for hematopoietic diseases.
  • Historically, HLA-identical sibling donors were preferred, limiting treatment options.
  • Graft failure, rejection, and graft-versus-host disease (GvHD) are complications, especially with HLA mismatches.

Purpose of the Study:

  • To review the evolution of donor selection in allogeneic marrow transplantation.
  • To highlight the success of HLA-identical unrelated donor transplants.
  • To emphasize the role of the National Marrow Donor Program in expanding access.

Main Methods:

  • Review of existing literature on allogeneic marrow transplantation and donor selection criteria.
  • Analysis of outcomes based on HLA compatibility between donor and recipient.

Related Experiment Videos

  • Examination of the impact of national donor registries.

    • Main Results:

    • While HLA-identical sibling donors remain optimal, successful transplants from partially matched relatives and HLA-identical unrelated donors are increasingly documented.
    • Increasing HLA incompatibilities correlate with higher risks of graft failure, rejection, and GvHD.
    • The National Marrow Donor Program has significantly increased the pool of HLA-typed potential donors.

    Conclusions:

    • Donor selection is critical for successful allogeneic marrow transplantation.
    • Unrelated donor transplants, facilitated by national registries, are expanding treatment availability.
    • Continued efforts in donor recruitment and matching are essential to improve outcomes for patients with hematopoietic system diseases.